Enthera’s €28M series A latest sign of growth for Italy’s biotech ecosystem
Autoimmune play Enthera first biotech to emerge from Italy’s BiovelocITA accelerator
U.S. and European investors are backing the largest-ever series A financing for an Italian biotech, autoimmune play Enthera s.r.l.
Enthera raised €28 million ($32.8 million) in the round, which was led by existing investor Sofinnova Partners and new investor AbbVie Ventures.
Italy has historically lacked a dedicated venture